Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023843 | 0.88 | TLR8 (0.40) | TLR8PTGS2CYP11B1HSD11B1SIGMAR1 | |
| SCHEMBL5023343 | 0.86 | TLR8 (0.43) | TLR8PTGS2CYP11B1HSD11B1SIGMAR1 | |
| SCHEMBL4678016 | 0.85 | TLR8 (0.42) | TLR8PTGS2CYP11B1F2RL3HSD11B1 | |
| SCHEMBL4415569 | 0.85 | RAD51 (0.42) | TLR8PTGS2CYP11B1F2RL3HSD11B1 | |
| SCHEMBL5023360 | 0.85 | TLR8 (0.42) | TLR8PTGS2CYP11B1F2RL3HSD11B1 | |
| SCHEMBL5023362 | 0.83 | PSEN1 (0.47) | PLA2G7MGLLABHD6ADORA3KDM2B | |
| SCHEMBL4682811 | 0.83 | TLR8 (0.41) | TLR8PTGS2RAD51ADORA3TRPV3 | |
| SCHEMBL5016834 | 0.82 | CTSS (0.39) | TLR8PTGS2F2RL3RAD51ADORA3 | |
| SCHEMBL508428 | 0.81 | MAPT (0.45) | F2RL3ADORA3TRPV3KDM2BKDM4C | |
| SCHEMBL4089672 | 0.81 | TRPV3 (0.43) | PTGS2RAD51TRPV3CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| CN-100467463-C | Pyrazolylindolyl derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7241793-B2 | Phenyloxyalkanonic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241793-B2 | Phenyloxyalkanonic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241793-B2 | Phenyloxyalkanonic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| CN-1930150-A | Pyrazolyl indolyl derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725546-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2005-10-06 | — | — | US | disclosed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
| WO-2005085235-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| EP-1513796-A2 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000785-A2 | PHENYLOXYALKANONIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | TLR8 727/4885PTGS2 529/4885CYP11B1 128/4885 |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | CEL, HPN, LIPA | TLR8 1797/4885PTGS2 665/4885CYP11B1 975/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | TLR8 727/4885PTGS2 529/4885CYP11B1 128/4885 |
| US-20050203160-A1 | Indolyl derivatives | PPARD, PPARA, PPARG | TLR8 828/4885PTGS2 1571/4885CYP11B1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.